摘要
目的探讨索拉非尼联合经皮肝动脉化疗栓塞术（TACE）治疗中晚期肝癌的疗效。方法选取30例中晚期肝癌患者,给予索拉非尼联合TACE治疗（试验组）,同时选取30例中晚期肝癌患者作为对照组仅行TACE;于1-2个治疗周期后比较临床疗效及生存质量卡氏评分。结果试验组与对照组,治疗3个月后临床获益率分别为83.3%、60.0%,差异有统计学意义（P〈0.05）,而生存质量卡氏评分2组差异无统计学意义（P〉0.05）;6个月生存率分别为93.3%、86.7%,差异无统计学意义（P〉0.05）,12个月生存率分别为86.4%、60.0%,差异有统计学意义（P〈0.05）。结论采用索拉非尼联合TACE治疗中晚期肝癌,可提高患者临床获益率及1年生存率。
Objective To study the clinical effect of sorafenib combination arterial cbemoembolization （TACE） for treatment of advanced hepatocellular with transcatheter carcinoma. Methods Thirty patients with advanced hepatocellular carcinoma were treated by sorafenib combination with TACE （experimental group） and other thirty patients were treated by single TACE （control group）. The clinical effect was evaluated after 1-2 treatment cycles according to response evaluation criteria in solid tumor and quality of life. Results The clinical benefit rate of experimental group and control group were 83.3 % and 60.0 % after 3 months treatment, the difference had statistical significance （P〈0.05）. The Karnofsky scores had no significant difference between two groups （P〉0.05）. The 6 months survival rate of experimental group and control group were 93.3% and 86.7% respectively （P〉0.05）. The 1-year survival rate were 86.4% and 60.0% respectively,and the experimental group was significantly higher than control group （P〈0.05）. Conclusion Sorafinib combination with TACE may improve the clinical benefit rate and 1-year survival rate of advanced hepatocellular carcinoma.
出处
《实用临床医学（江西）》
CAS
2009年第11期17-19,共3页
Practical Clinical Medicine
关键词
索拉非尼
TACE
肝癌
sorafinib
TACE
hepatocellular carcinoma
